- Home
- JAZZ vs BEP Comparison
JAZZ vs BEP Comparison
Compare JAZZ & BEP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JAZZ
- BEP
- Stock Information
- Founded
- JAZZ 2003
- BEP 1999
- Country
- JAZZ Ireland
- BEP Canada
- Employees
- JAZZ N/A
- BEP N/A
- Industry
- JAZZ Biotechnology: Pharmaceutical Preparations
- BEP Electric Utilities: Central
- Sector
- JAZZ Health Care
- BEP Utilities
- Exchange
- JAZZ Nasdaq
- BEP Nasdaq
- Market Cap
- JAZZ 7.1B
- BEP 7.3B
- IPO Year
- JAZZ 2007
- BEP N/A
- Fundamental
- Price
- JAZZ $124.15
- BEP $25.54
- Analyst Decision
- JAZZ Strong Buy
- BEP Buy
- Analyst Count
- JAZZ 12
- BEP 8
- Target Price
- JAZZ $182.75
- BEP $31.25
- AVG Volume (30 Days)
- JAZZ 879.8K
- BEP 465.4K
- Earning Date
- JAZZ 08-05-2025
- BEP 08-01-2025
- Dividend Yield
- JAZZ N/A
- BEP 5.76%
- EPS Growth
- JAZZ N/A
- BEP N/A
- EPS
- JAZZ N/A
- BEP N/A
- Revenue
- JAZZ $4,086,695,000.00
- BEP $6,174,000,000.00
- Revenue This Year
- JAZZ $5.65
- BEP $18.12
- Revenue Next Year
- JAZZ $5.79
- BEP $5.94
- P/E Ratio
- JAZZ N/A
- BEP N/A
- Revenue Growth
- JAZZ 4.52
- BEP 12.75
- 52 Week Low
- JAZZ $95.49
- BEP $19.29
- 52 Week High
- JAZZ $148.06
- BEP $29.56
- Technical
- Relative Strength Index (RSI)
- JAZZ 66.76
- BEP 51.06
- Support Level
- JAZZ $122.50
- BEP $24.62
- Resistance Level
- JAZZ $126.14
- BEP $25.62
- Average True Range (ATR)
- JAZZ 2.50
- BEP 0.44
- MACD
- JAZZ 0.80
- BEP 0.09
- Stochastic Oscillator
- JAZZ 87.44
- BEP 94.62
About JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
About BEP Brookfield Renewable Partners L.P.
Brookfield Renewable is a globally diversified, multitechnology owner and operator of clean energy assets. The company's portfolio consists of hydroelectric, wind, solar, and storage facilities in North America, South America, Europe, and Asia and totals over 40 gigawatts of installed capacity. Brookfield Renewable invests in assets directly, as well as with institutional partners, joint venture partners, and through other arrangements. The company offers two separate listings for investors: Brookfield Renewable Partners and Brookfield Renewable Corp.